By Vaibhav Patel, University of Minnesota
Published in: Pharmaceutical OnLine
Published on: September 11, 2024
This article explores the significance of the FDA’s latest recommendations, explaining the nature of nitrosamine impurities, their root causes, and recommended strategies for mitigating their presence in pharmaceuticals. We also will discuss the implications of these recommendations for the global pharmaceutical industry and outline the best practices for ensuring compliance with the FDA guidelines.
